


NRG Concept OV1719
Olaparib-Tremelimumab vs PCT





(Group-Wide)

Preliminary data from pilot clinical trial at U New Mexico (INST1419)


Potential Mechanisms:

- Therapeutic synergy in immunocompetent murine tumor model with BRCA1m OvCa
- PARPi-mediated immunogenicity through increased expression of MHC1 and Fas
- Role of IFN-γ as mediator and predictive marker (exploratory endpoint)




Olaparib 300mg PO twice daily. Tremelimumab IV 10mg/kg monthly x6 then every 3 m for up to two years

NRG Concept OV1719
Olaparib-Tremelimumab vs PCT



(Group-Wide)

- Recurrent HGSC with PFI > 6 months (following most recent platinum)
- No more than 3 prior regimens (including primary therapy)
- RECIST measurable disease
- No prior PARPi therapy or immune checkpoint inhibitors
- Primary endpoint: PFS (pre-specified sequential analysis by whole population and subgroups)




Open:
 Status: Concept in planning
 Target: 420 pts (126 BRCAm+, 168 HRD+, 126 HRD-)
 Notes: OTF review 20-OCT-2017 then GCSC

NRG Concept OV1741
NACT +/- ICS



(Group-Wide)

- Epithelial ovarian, peritoneal, or fallopian carcinoma (EOPFC)
- Stage IIIC-IV and suitable for NACT with interval cytoreductive surgery
- Registered after CT with minimal residual disease, prior to planned ICS
- Permits minimally-invasive ICS
- Primary Endpoints: PFS and PRO/QoL



CP = Carboplatin AUC 6 (D1), Paclitaxel 80 mg/m² (D1,8,15)
 CT-MRD = CT post-chemotherapy with minimal residual disease
 ICS = Interval Cytoreductive Surgery (minimally invasive allowed)

Open:
 Status: Concept in planning
 Target: Approximately 150 pts
 Notes: Evaluating options for NCI support (DCP or CTEP)